NOCA4: A Potential Drug Target for Pain and Anxiety (G8031)

Target Name: NCOA4

NCBI ID: G8031

NCOA4

NOCA4: A Potential Drug Target for Pain and Anxiety

The Nuclear Receiver Coactivator 4 (NOCA4) gene is a protein that plays a crucial role in nuclear receptor signaling. It is a member of the nuclear receptor coactivator family, which includes a variety of genes that help regulate gene expression in response to various signaling pathways. One of the key functions of NOCA4 is to enhance the activity of nuclear receptors, which are proteins that interact with DNA to regulate gene expression.

The NOCA4 gene has four splice variants, which are the NOCA4-1, NOCA4-2, NOCA4-3, and NOCA4-4 transcript variants. These variants differ in the way the gene is spliced, which can result in differences in the length and sequence of the final protein product. The most abundant variant is NOCA4-1, which is the NOCA4 gene that is typically used to study the function of NOCA4.

NOCA4 is a key coactivator of several nuclear receptors, including the delta-opioid receptor, the GABA receptor, and the steroid receptor. It is involved in the regulation of pain, inflammation, and other physiological processes. NOCA4 is also involved in the regulation of behavioral processes, such as anxiety and fear.

In addition to its role in nuclear receptor signaling, NOCA4 is also a potential drug target. Several studies have suggested that NOCA4 may be a useful target for the development of new treatments for various diseases, including cancer, anxiety, and depression.

One potential mechanism by which NOCA4 could be targeted by drugs is through its role in pain signaling. NOCA4 is known to be involved in the regulation of pain perception and sensitivity, and it has been shown to play a role in the development of chronic pain. By targeting NOCA4, drugs could potentially reduce pain sensitivity and improve pain relief.

Another potential mechanism by which NOCA4 could be targeted by drugs is through its role in the regulation of anxiety and depression. NOCA4 has been shown to be involved in the regulation of anxiety and depression, and it has been suggested as a potential therapeutic target for these conditions. By blocking the activity of NOCA4, drugs could potentially reduce anxiety and depression symptoms.

In addition to its potential as a drug target, NOCA4 is also a potential biomarker for certain diseases. The NOCA4 gene has been shown to be expressed in a variety of tissues and cells, including brain, heart, and peripheral tissues. This suggests that NOCA4 could be a useful biomarker for the diagnosis and monitoring of certain diseases.

Overall, the NOCA4 gene is a promising target for the development of new drugs and therapies. Further research is needed to fully understand the role of NOCA4 in nuclear receptor signaling and its potential as a drug and biomarker.

Protein Name: Nuclear Receptor Coactivator 4

Functions: Enhances the androgen receptor transcriptional activity in prostate cancer cells. Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma

The "NCOA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCOA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets